Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
Tachyon Therapeutics has raised $11.6M in total funding. The most recent round was Series A. The last funding was announced in March 2023.
Tachyon Therapeutics's investors include Khosla Ventures, Red Tree Venture Capital, California Institute for Regenerative Medicine, Veblen Ventures.
Tachyon Therapeutics is headquartered in San Francisco, United States.
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
Tachyon Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tachyon Therapeutics — Funding & Investors." VCBacked, March 1, 2023, https://www.vcbacked.co/company/tachyon-therapeutics. Accessed August 14, 2026.
VCBacked. (2023). Tachyon Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tachyon-therapeutics
{{cite web |title=Tachyon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tachyon-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated